Max HealthcareQ3 FY24

Max Healthcare Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,030.9P/E: 70.6Market Cap: ₹1.0L CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Network gross revenue grew 16% YoY for the nine months ended Dec 2023; Q3 revenue grew 14% YoY.
  • Average Revenue Per Occupied Bed (ARPOB) is expected to grow reasonably at 9-10% driven by price increases, OPD growth, oncology growth, and improved case/channel mix.
  • International patient revenue grew 25% YoY, supporting revenue growth.
  • Expansion adding around 800-1000 beds over next 5-6 years expected to be quickly absorbed due to high demand and occupancy constraints.
  • Brownfield expansions like Shalimar Bagh show new beds ramp up quickly and contribute positive EBITDA and operating margins.
  • Oncology, including robotics and immunotherapy, is a key growth driver, with higher EBITDA per bed.
  • Institutional business tariffs may be revised upwards, potentially increasing revenue.
  • Seasonal patterns: Q2 & Q4 typically strongest quarters.
  • Overall, a robust Q4 is expected due to seasonality and continued growth momentum.

See what Max Healthcare management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or immediate new fundraising through debt or equity in the provided pages.
  • The company highlights strong free cash flow generation (Rs. 924 crore over nine months), which is being used for expansion and dividends.
  • Expansion projects (Dwarka, Nanavati, Gurgaon, Mohali, Saket Complex) are largely funded through internal cash flows, with no indication of new external financing.
  • Abhay Soi mentioned having sufficient wherewithal to add 3-4 hospitals within 1-2 years without stressing the balance sheet.
  • For Lucknow, large-scale future capacity expansions post FY28 are described as potential, with no approved CAPEX or Board approvals currently.
  • Overall, the company appears financially comfortable funding growth organically without aggressive external fundraising plans at this time.

See what Max Healthcare management said on order book — free account, 30 seconds.

Capex plans

Yes
- Dwarka hospital (300 beds): Near commissioning; asset-light model with lease contract; minimal future CAPEX expected; finishing in progress. - Nanavati (329 beds): Basement and ground level completed; steel fabrication started; on schedule. - Sector-56 Gurgaon (300 beds): Structural drawing approved; RCC works commenced; on schedule. - Mohali (190 beds): Design finalized; base raft concrete started; on schedule. - Max Smart (Saket Complex, 350 beds): Tree transplantation underway; existing structures demolished; project progressing after initial delay. - Max Vikrant (Saket Complex, 300 beds): Revised building plans submitted; infrastructure dues paid; contractor tenders under review; Forest department NOC applied. - Expected CAPEX for FY24 is Rs. 900 crore (tracking Rs. 300 crore so far). - Lucknow expansion has land for significant future capacity (up to 3500 beds possible post-2028); construction and expansion will be phased. - Brownfield expansions like Shalimar Bagh are preferred for quicker bed additions with better operating leverage. Overall, multiple large-scale projects are underway with planned commissioning over next 1-3 years and further strategic expansions contemplated.

Track Max Healthcare — get its next earnings analysis in your feed

How does Max Healthcare rank vs peers in Healthcare Services?

Pro feature
ThisMax Healthcare
Rev 3Mar 3

How does Max Healthcare rank in Healthcare Services?

Compare Max Healthcare against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →